Wang K, Yu H-M, Xiang Y-J, et al. Efficacy and safety of radiotherapy combined with atezolizumab plus bevacizumab in treating hepatocellular carcinoma with portal vein tumour thrombus: a study protocol. BMJ Open 2022;12:e064688. doi:10.1136/ bmjopen-2022-064688
This article has been corrected since it was published online.
In the Method and Analysis section of the Abstract:
The sentence currently reads: ‘Assuming an ORR of 47%, with a two-sided alpha error of 0.1, 90% power, and a 10% drop-out rate, the required number of evaluable patients is 42.’
It should be corrected to: ‘Assuming an ORR of 47%, with a one-sided alpha error of 0.1, 90% power, and a 10% drop-out rate, the required number of evaluable patients is 42.’
In the Statistical Methods section:
The sentence currently reads: ‘Hence, assuming an ORR of 47% after discussion among investigators based on the experience, with a two-sided alpha error of 0.1, 90% power, and 10% drop-out rate, the required number of evaluable patients is 42.’
It should be corrected to: ‘Hence, assuming an ORR of 47% after discussion among investigators based on the experience, with a one-sided alpha error of 0.1, 90% power, and 10% drop-out rate, the required number of evaluable patients is 42.